

Date: 01/06/2020

To,  
The Manager  
Listing department,  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block-G,  
Bandra Kurla Complex, Bandra (E),  
Mumbai- 400 051  
Maharashtra

**Subject: Outcome of the Board Meeting held on Monday, 1<sup>st</sup> day of June, 2020 in terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015**

**Ref.: Symbol- PAR (NSE Emerge), ISIN: INE04LG01015**

Dear Sir/Madam,

The meeting of Board of Directors of the Company held on **Monday, 1<sup>st</sup> day of June, 2020** at **3:30 PM** through Video Conferencing ("VC") mode inter alia transacted the following business:

Item No.	Outcomes
1.	Pursuant to section 184(1) of the Companies Act, 2013, each director placed FORM MBP – 1 and board took note that there is no change during the year in his/her concern or interest in any company or companies or bodies corporate, firms, or other association of individuals including shareholding of each director.
2.	Pursuant to section 164 (2) of the Companies Act, 2013, each director placed FORM DIR-8 and board took note that none of the directors are disqualified pursuant to section 164 (2).
3.	Board took note of the declarations received from all the Independent Directors in compliance with section 149 (6) of the Companies act, 2013.
4.	Board took note of resolutions passed by circulations.
5.	The board received, considered and approved the audited financial results for half year and year ended on 31 <sup>st</sup> March, 2020 along with statement of assets and liabilities, statement of profit & loss and cash flow statement together with Auditors Report with <b>unmodified opinion thereon</b> . The said Audited Financial Results along with Auditors' Report, Declaration pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended time to time, and Certificate of correctness of Financial statement pursuant to Regulation 33(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended time to time are attached herewith (Annexure-1, 2 & 3). The above audited financial results were reviewed by Audit Committee at its meeting.
6.	Board received, considered and approved Annual Audited financial statement with Audit Report for F.Y. 2019-20 ended on 31 <sup>st</sup> March, 2020.
7.	Board received and considered Secretarial Audit Report on the Secretarial records of the Company for the year ended 31 <sup>st</sup> March, 2020 as placed before the Board and initialed by the Chairman for the purpose of identification and approved and the same is recommended to the members for adoption in forthcoming ensuring Annual General Meeting.
8.	Board received, considered and approved Internal Audit Report on the basis of internal audit conducted by M/s. SIDDHPURA & CO, Chartered Accountants for F.Y. 2019-20.
9.	The Board recommended to the members the final Dividend for the financial year 2019-20 on Equity Shares at the rate of 12.50 % i.e. 1.25/- per equity share of the face value of 10/- each out of profit of the company for the financial year ended on 31 <sup>st</sup> March, 2020. The final dividend amount will be paid after approval of shareholders in forthcoming ensuring Annual General

	<p>Meeting of the Company.</p> <p>The record date will be intimated in due of course time in terms of Regulation 42 (Listing Obligations and Disclosure Requirements) Regulation, 2015.</p>
10.	The Board took note of statement of Deviation / Variation in utilization of funds raised through public issue for the half year ended 31 <sup>st</sup> March, 2020.
11.	The Board took note of Investor Grievance Report for the quarter ended 31 <sup>st</sup> March, 2020 and review the SCORES platform of SEBI to solve the investor compliant till date, if any
12.	Board received, considered and approved Human Resource Annual Report as presented by the HR head of the Company to the management and recommended some improvement of HR Department efficiency for the next year.
13.	The Board took note of Actuarial valuation report as per AS 15 under the defined benefit scheme of Gratuity Benefits for the financial year ended 31 <sup>st</sup> March, 2020 received from Kapdiya Actuaries & Consultant of Mr. Saurabh Kochrekar, Fellow of Institute of Actuaries of India (ID: 19005)
14.	Board decided to hold the decision of appointment of the Independent director and will considered it in future.
15.	The Board considered and approved the appointment of M/s DG Patel & Associates, Company Secretaries (FCS No. 10533, C.P. No.: 13774) as Secretarial Auditors of the Company pursuant to Section 204 of the Companies Act, 2013 for conducting secretarial audit for the F.Y. 2020-21. The Profile of Secretarial Auditors is attached herewith (Annexure-4)
16.	The Board considered and approved the appointment of M/s V Dhamsania & Associates, Chartered Accountants, having FRN 132499W as GST auditor of the Company for the of F.Y 2020-21. The profile of GST Auditors is attached herewith (Annexure-5)
17.	The Board authorized to M/s DG Patel & Associates, Company Secretaries (FCS No. 10533, C.P. No.: 13774) to issue Annual Secretarial Compliance Report for the F.Y. 2019-20 in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/27/2019 dated February 08, 2019.
18.	The board decided not to give advertisement of financial result in the newspaper due to non-requirement of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended time to time for SME Listed Companies.
19.	The Board took note of SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/84 dated May 20, 2020 on disclosure of material impact of CoVID-19 pandemic on listed entities under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('LODR Regulations'/'LODR) and approved the statement for the same for submission at NSE-Emerge Platform.
20.	The Board considered and authorized Mr. Jignesh V. Savani, Director & CEO of the Company to file E-Form No. DPT-3 with Registrar of Companies for the financial year ended on 31 <sup>st</sup> March, 2020.
21.	The Board considered and authorized Mr. Jignesh V. Savani, Director & CEO of the Company to file MSME FORM I for half yearly return with Registrar of Companies, if required
22.	The Board reviewed all policies of the Company.
23.	Board reviewed terms and Conditions of appointment of Independent Directors
24.	Board reviewed the code of conduct of the company.
25.	There being no other item to be discussed and taken for proposal.

Further, in continuation of our intimation dated 30<sup>th</sup> March, 2020 and pursuant to Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and amendment made time to time till date and according to Company's Code of Conduct to Regulate, Monitor and Report Trading by Insiders, the trading window for trading in securities of the Company will remain closed till the record date determined by the board in the forthcoming board meeting for the purpose of dividend which is subject to approval of members at the forthcoming AGM, for Designated persons, Designated employees and their Immediate relatives.

The Board Meeting was commenced at 3:45 PM and concluded at 5:47 PM.

Kindly take on the record and acknowledge the receipt.

Yours Faithfully,

**For PAR DRUGS AND CHEMICALS LIMITED**

---

**(Sanket B. Trivedi)**

**Company Secretary & Compliance Officer**

**Annexure:**

1. Financial statements include statement of assets and liabilities, statement of profit & loss and cash flow statement together with Auditor's Report
2. Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015
3. Certificate of Correctness of financial Statement
4. Profile of Secretarial Auditor
5. Profile of GST Auditor



INDEPENDENT AUDITOR'S REPORT

(Auditor's Report on Standalone Financial Results pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015)

TO  
THE BOARD OF DIRECTORS OF  
PAR DRUGS AND CHEMICALS LIMITED

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying standalone half yearly financial results of **PAR DRUGS AND CHEMICALS LIMITED** (the company) for the **half year ended 31<sup>st</sup> March, 2020** and the year to date results for the period from **1<sup>st</sup> April, 2019 to 31<sup>st</sup> March, 2020**, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:


- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the **net profit** and other comprehensive income and other financial information for the half year ended **31<sup>st</sup> March, 2020** as well as the year to date results for the period from **1<sup>st</sup> April, 2019 to 31<sup>st</sup> March, 2020**

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

These half yearly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net



Bhavnagar: 320, Imperial Arc, Opp University Gate, Waghawadi Road, Bhavnagar-364001

Surat: Office No.-1, Tulsi Arcade, Opp. Gabani Hospital, Station Road, Surat-395003

Cell : +91 - 9898027172 / Phone No : 0278-2570300

E-Mail : vipuldhamsania@gmail.com



profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

#### **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.

Bhavnagar: 320, Imperial Arc, Opp University Gate, Waghawadi Road, Bhavnagar-364001

Surat: Office No.-1, Tulsi Arcade, Opp. Gabani Hospital, Station Road, Surat-395003

Cell : +91 - 9898027172 / Phone No : 0278-2570300

E-Mail : vipuldhamsania@gmail.com




- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

V DHAMSANIA & ASSOCIATES  
(Firm Regn No. – 132499W)  
CHARTERED ACCOUNTANTS



VIPUL V DHAMSANIA (Partner)  
M.No.140836  
Bhavnagar, 1<sup>st</sup> June, 2020  
UDIN - 20140836AAAAED9708

**PAR DRUGS AND CHEMICALS LIMITED**

(CIN : L24117GJ1999PLC035512)

**Registered Office : 805, Dwarkesh Complex, R C Dutt Road, Alkapuri, Vadodara (Gujarat)**

**Audited Financial Results for the Half Year Ended 31st March, 2020**

**Statement Of Assets And Liabilities**

**Rs. In Lakhs**

Particulars		AS AT 31.03.2020	AS AT 31.03.2019
		Audited	Audited
I.	<b>EQUITY AND LIABILITIES</b>		
1	<b>Shareholders' funds</b>		
(a)	Share capital	615.23	448.03
(b)	Reserves and surplus	3,446.22	2,454.86
(c)	Money received against share warrants	0.00	0.00
	<b>Sub-total (1)</b>	<b>4,061.45</b>	<b>2,902.89</b>
2	<b>Share application money pending allotment</b>	0.00	0.00
3	<b>Non-current liabilities</b>		
(a)	Long-term borrowings	461.91	603.14
(b)	Deferred tax liabilities (Net)	365.12	342.43
(c)	Other Long term liabilities	0.00	0.00
(d)	Long-term provisions	38.62	32.69
	<b>Sub-total (2)</b>	<b>865.65</b>	<b>978.27</b>
4	<b>Current liabilities</b>		
(a)	Short-term borrowings	0.00	431.91
(b)	Trade payables		
	Due to Micro, Small & Medium Enterprise	0.00	0.00
	Due to Others	620.46	493.18
(c)	Other current liabilities	269.10	233.15
(d)	Short-term provisions	194.85	87.32
	<b>Sub-total (3)</b>	<b>1,084.42</b>	<b>1,245.57</b>
	<b>TOTAL</b>	<b>6,011.52</b>	<b>5,126.73</b>
II.	<b>ASSETS</b>		
	<b>Non-current assets</b>		
1	(a) Property, Plant and Equipment		
	(i) Tangible assets	3,439.62	3,634.10
	(ii) Intangible assets	0.00	0.00
	(iii) Capital work-in-progress	73.90	0.00
	(iv) Intangible assets under development	0.00	0.00
		<b>3,513.52</b>	<b>3,634.10</b>
(b)	Non-current investments	5.65	5.65
(c)	Deferred tax assets (net)	0.00	0.00
(d)	Long-term loans and advances	70.50	68.58
(e)	Other non-current assets	0.00	0.00
	<b>Sub-total (1)</b>	<b>3,589.67</b>	<b>3,708.33</b>
2	<b>Current assets</b>		
(a)	Current investments	0.00	0.00
(b)	Inventories	291.68	429.41
(c)	Trade receivables	1,236.84	851.97
(d)	Cash and cash equivalents	737.92	3.06
(e)	Short-term loans and advances	62.27	61.05
(f)	Other current assets	93.14	72.92
	<b>Sub-total (2)</b>	<b>2,421.85</b>	<b>1,418.40</b>
	<b>TOTAL</b>	<b>6,011.52</b>	<b>5,126.73</b>

**For and on behalf of Board of Directors  
Par Drugs and Chemicals Limited**

**Jigneshbhai V Savani (CEO)**  
(DIN - 00198203)  
Bhavnagar, 1st June, 2020

**Falgun V Savani (Managing Director)**  
(DIN - 00198236)  
Bhavnagar, 1st June, 2020

**PAR DRUGS AND CHEMICALS LIMITED**

(CIN : L24117GJ1999PLC035512)

Registered Office : 805, Dwarkesh Complex, R C Dutt Road, Alkapuri, Vadodara (Gujarat)

Audited Financial Results for the Half Year Ended 31st March, 2020

**Statement Of Profit & Loss**

Rs. In Lakhs

Particulars	Half Year Ended			Year Ended	
	31.03.2020	30.09.2019	31.03.2019	31.03.2020	31.03.2019
	Audited	Unaudited	Unaudited	Audited	Audited
I. Revenue from operations	2,673.73	2,911.14	2,146.17	5,584.87	4,632.33
II. Other income	9.68	0.17	8.87	9.86	8.87
<b>III. Total Revenue (I + II)</b>	<b>2,683.41</b>	<b>2,911.32</b>	<b>2,155.04</b>	<b>5,594.72</b>	<b>4,641.20</b>
<b>IV. Expenses:</b>					
Cost of materials consumed	1,070.34	1,148.78	889.83	2,219.12	1,922.04
Purchases of Stock-in-Trade	0.00	0.00	0.00	0.00	0.00
Changes in inventories of finished goods work-in-progress and Stock-in-Trade	63.18	83.27	-49.02	146.45	0.11
Employee benefits expense	207.37	203.99	158.32	411.36	363.91
Finance costs	37.48	41.91	82.27	79.39	196.30
Depreciation and amortization expense	6.60	269.55	171.11	276.15	303.70
Other expenses	909.75	953.32	782.71	1,863.06	1,525.98
<b>Total expenses (IV)</b>	<b>2,294.71</b>	<b>2,700.83</b>	<b>2,035.21</b>	<b>4,995.54</b>	<b>4,312.04</b>
<b>V. Profit before exceptional and extraordinary items and tax (III-IV)</b>	<b>388.70</b>	<b>210.49</b>	<b>119.83</b>	<b>599.19</b>	<b>329.17</b>
VI. Exceptional items	0.00	0.00	0.00	0.00	0.00
<b>VII. Profit before extraordinary items and tax (V - VI)</b>	<b>388.70</b>	<b>210.49</b>	<b>119.83</b>	<b>599.19</b>	<b>329.17</b>
VIII. Extraordinary Items	0.00	0.00	0.00	0.00	0.00
<b>IX. Profit before tax (VII- VIII)</b>	<b>388.70</b>	<b>210.49</b>	<b>119.83</b>	<b>599.19</b>	<b>329.17</b>
X Tax expense:					
(1) Current tax	56.70	43.30	67.80	100.00	67.80
(2) Deferred tax	14.37	8.32	10.26	22.69	10.26
<b>XI Profit (Loss) for the period from continuing operations (VII-VIII)</b>	<b>317.63</b>	<b>158.86</b>	<b>41.77</b>	<b>476.50</b>	<b>251.10</b>
XII Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00
XIII Tax expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00
<b>XIV Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>XV Profit (Loss) for the period (XI + XIV)</b>	<b>317.63</b>	<b>158.86</b>	<b>41.77</b>	<b>476.50</b>	<b>251.10</b>
XVI Earnings per equity share:					
(1) Basic.	5.16	2.58	0.93	7.75	5.60
(2) Diluted.	5.16	2.58	0.93	7.75	5.60

For and on behalf of Board of Directors  
Par Drugs and Chemicals Limited

\_\_\_\_\_  
Jigneshbhai V Savani (CEO)  
(DIN - 00198203)  
Bhavnagar, 1st June, 2020

\_\_\_\_\_  
Falgun V Savani (Managing Director)  
(DIN - 00198236)  
Bhavnagar, 1st June, 2020

**PAR DRUGS AND CHEMICALS LIMITED**  
(CIN : L24117GJ1999PLC035512)  
Registered Office : 805, Dwarkesh Complex, R C Dutt Road, Alkapuri, Vadodara (Gujarat)  
Audited Financial Results for the Half Year Ended 31st March, 2020  
**Statement of Cash Flow**

Particulars	Rs. In Lakhs			
	Half Year Ended		Year Ended	
	31.03.2020	30.09.2019	31.03.2020	31.03.2019
	Audited	Unaudited	Audited	Audited
<b>A: CASH FLOW FROM OPERATING ACTIVITIES:</b>				
Net profit before tax as per P & L Statement.	388.70	210.49	599.19	329.17
<u>Adjusted for:</u>				
Depreciation	6.60	269.55	276.15	303.70
Income-tax/Prior Year Adjustment	0.00	-1.04	-1.04	-44.61
Interest Expense	61.76	13.64	75.41	181.15
Rent, Interest & Dividend Income	-7.47	-0.17	-7.65	-8.87
Profit/Loss on sale of assets	-2.21	0.00	-2.21	0.00
	58.68	281.98	340.66	431.37
	<b>447.38</b>	<b>492.47</b>	<b>939.85</b>	<b>760.54</b>
<b>Operating Profit /(loss) before working capital changes</b>				
<u>Adjustments for changes in working capital</u>				
Adjustments for (increase)/decrease in operating assets				
Long Term Loans & Advances	8.24	-10.17	-1.92	1.00
Inventories	21.67	116.06	137.73	-22.66
Trade Receivables.	5.29	-390.15	-384.86	20.49
Short Term Loans & Advances	8.83	-10.06	-1.23	7.80
Other Current Assets	-3.48	0.72	-2.76	0.34
Adjustments for increase/(decrease) in operating liabilities				
Long-term provisions	5.93	0.00	5.93	32.69
Short-term provisions	-7.00	5.43	-1.57	19.52
Other Current Liabilities	68.42	-32.48	35.95	-379.81
Trade Payables	-75.05	202.33	127.28	-32.95
	<b>32.86</b>	<b>-118.32</b>	<b>-85.46</b>	<b>-353.58</b>
<b>Cash Generated from / (used in) Operating activities</b>	<b>480.24</b>	<b>374.14</b>	<b>854.39</b>	<b>406.95</b>
Less: Income-Tax paid	-42.29	-42.97	-85.27	-71.02
	<b>437.95</b>	<b>331.17</b>	<b>769.12</b>	<b>335.93</b>
<b>Net Cash generated from / (used in) Operating Activities:</b>				
<b>B: CASH FLOW FROM INVESTING ACTIVITIES:</b>				
Purchase of Fixed Assets	-137.03	-18.84	-155.87	-34.30
Sales of Fixed Assets	2.50	0.00	2.50	0.00
Rent, Interest & Dividend Income	7.47	0.17	7.65	8.87
	<b>-127.06</b>	<b>-18.66</b>	<b>-145.72</b>	<b>-25.43</b>
<b>Net Cash generated from / (used in) Investing Activities:</b>				
<b>C: CASH FLOW FROM FINANCING ACTIVITIES:</b>				
Proceeds from Issue of Shares	0.00	852.72	852.72	600.00
Proceeds from Long Term Borrowings	0.00	0.00	0.00	0.00
Repayment of Long Term Borrowings	-148.47	7.24	-141.23	-656.32
Repayment of Short Term Borrowings	0.00	-431.91	-431.91	-76.34
Dividend Paid	-75.41	0.00	-75.41	-181.15
Dividend Tax paid	0.00	0.00	0.00	0.00
Interest paid	13.64	-13.64	0.00	0.00
	<b>-302.95</b>	<b>414.41</b>	<b>111.46</b>	<b>-313.82</b>
<b>Net Cash generated from / (used in) Financing Activities:</b>				
<b>Net Increase/(Decrease) in Cash and Cash Equivalents</b>	<b>7.94</b>	<b>726.92</b>	<b>734.86</b>	<b>-3.32</b>
<b>Opening Balance of Cash and Cash Equivalents</b>	729.97	3.06	3.06	6.38
<b>Closing Balance of Cash and Cash Equivalents</b>	737.92	729.97	737.92	3.06
<b>Total:</b>	<b>7.94</b>	<b>726.92</b>	<b>734.86</b>	<b>-3.32</b>

1. Purchase of fixed assets are stated inclusive of movement of Capital Work in Progress and advance for capital goods between the commencement and end of the year and are considered as part of investing activity.

2. The cash flow statement has been prepared under the "indirect method" as set out in Accounting Standard - 3 on Cash Flow Statement issued by the Institute of Chartered Accountants of India.

For and on behalf of Board of Directors  
Par Drugs and Chemicals Limited

Jigneshbhai V Savani (CEO)  
(DIN - 00198203)  
Bhavnagar, 1st June, 2020

Falgun V Savani (Managing Director)  
(DIN - 00198236)  
Bhavnagar, 1st June, 2020

## **PAR DRUGS AND CHEMICALS LIMITED**

### **NOTES:**

1. Above audited financial results have been reviewed by audit committee in their meeting held on 30th May, 2020 and approved by the Board of Directors in their meeting held on 1st June, 2020
2. The Auditor of the company have carried out a audit of the financial results for the half year and year ended 31st March, 2020 in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015 and have expressed their unqualified opinion.
3. Figures for the half year ended 31st March, 2020 are balancing figures between audited figures in respect of full financial year and the published year to date figures of the first half year. The figures up to the end of the half year ended 30th September, 2019 were subject to limited review.
4. Previous year / period figures have been regrouped / rearranged wherever necessary to make them comparable with current period figures.
5. The Company is primarily engaged in manufacturing of API, which constitute single business segment in terms of Accounting Standard 17 on Segment Reporting. Accordingly, there are no other business segments to be reported under Accounting Standard 17.
6. The Company does not have any subsidiary, associates or joint venture as on 31<sup>st</sup> March, 2020; therefore, it has prepared only standalone results as consolidation requirement is not applicable to the Company.
7. The Bank Balance is included in Cash and Cash Equivalents of the Company.
8. The above financials are available on the Company's website – [www.pardrugs.com](http://www.pardrugs.com).
9. The Status of investors complaints received by the Company are as follows:
  - I. Received during the period from 1<sup>st</sup> October, 2019 to 31<sup>st</sup> March, 2020: NIL
  - II. Disposed during the period from 1<sup>st</sup> October, 2019 to 31<sup>st</sup> March, 2020: NIL
  - III. Pending as on 31<sup>st</sup> March, 2020: NIL

**For and on behalf of Board of Directors**

**Par Drugs and Chemicals Limited**

**Falgun V Savani (Managing Director)**  
**(DIN - 00198236)**

**Jigneshbhai V Savani (CEO)**  
**(DIN - 00198203)**

**Bhavnagar, 1<sup>st</sup> June, 2020**



DRUGS AND CHEMICALS LIMITED

**Registered Office :** 805, Dwarkesh Complex, R. C. Dutt Road, Alkapuri, Vadodara - 390 007. Gujarat (INDIA). | **Ph. :** +91-265-2342018 / 2332018 | **Fax :** +91-265-2332018

**Corporate Office :** 302, Anmol Plaza, Waghawadi Road, Bhavnagar. | **Ph. :** +91-278-2447013

**Email :** admin@pardrugs.com

**CIN No. :** L24117GJ1999PLC035512


[www.pardrugs.com](http://www.pardrugs.com)

To,  
The Board of Directors  
Par Drugs And Chemicals Limited

## CERTIFICATE OF CORRECTNESS OF FINANCIAL RESULTS

Pursuant to Regulation 33(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby certify that the financial results of the Company for the half year & year ended 31<sup>st</sup> March, 2020 placed before the meeting the financial results do not contain any false or misleading statement or figures and do not omit any material fact which may make the statements or figures contained therein misleading.

For Par Drugs And Chemicals Limited


  
(Mr. Jignesh V. Savani)  
Chief Executive Officer




Date: 01/06/2020

Place: Bhavnagar

For Par Drugs And Chemicals Limited

  
(Mr. Chintan P. Chauhan)  
Chief Financial Officer





DRUGS AND CHEMICALS LIMITED

**Registered Office :** 805, Dwarkesh Complex, R. C. Dutt Road, Alkapuri, Vadodara - 390 007. Gujarat (INDIA). | **Ph. :** +91-265-2342018 / 2332018 | **Fax :** +91-265-2332018

**Corporate Office :** 302, Anmol Plaza, Waghawadi Road, Bhavnagar. | **Ph. :** +91-278-2447013

**Email :** admin@pardrugs.com

**CIN No. :** L24117GJ1999PLC035512

www.pardrugs.com

To,  
The Manager  
Listing department,  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block-G,  
Bandra Kurla Complex, Bandra (E),  
Mumbai- 400 051  
Maharashtra

**Date:01-06-2020**

Subject: Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015

Ref.: **Symbol- PAR (NSE Emerge), ISIN: INE04LG01015**

Dear Sir/Madam,


I, **Chintan P. Chauhan, Chief Financial Officer** of Par Drugs And Chemicals Limited hereby declare that the Statutory Auditors of the Company, M/s V Dhamsania & Associates, Chartered Accountants, having FRN 132499W, Partnership Firm has issued an Audit Report with unmodified opinion on Audited Standalone Financial Results of the Company for the financial year ended March 31, 2020.


This declaration is given pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016, vide Notification No. SEBI/LAD-NRO/GN/2016-17/001 dated May 25, 2016 and Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016.

Kindly take on the record and acknowledge the receipt

Yours Faithfully

**For PAR DRUGS AND CHEMICALS LIMITED**

  
(Chintan P. Chauhan)  
Chief Financial Officer





# DG PATEL & ASSOCIATES

## COMPANY SECRETARIES

---

### PROFILE OF SECRETARIAL AUDITOR

M/S D G PATEL & ASSOCIATES, Company Secretaries, was established in the year 2014 and registered with the Institute of Company Secretaries of India (ICSI) vide COP No. 13774. Mr. Dip Girishbhai Patel is proprietor of the firm and is a Fellow member of the Institute of Company Secretaries of India.

M/S D G PATEL & ASSOCIATES offers services in area of Corporate Laws, Securities Laws, Corporate Governance matters, Due Diligence, Legal drafting of agreements etc.

**FOR DG PATEL & ASSOCIATES**  
**Company Secretaries**  
sd/-

\_\_\_\_\_  
**Dip G. Patel**  
**(Proprietor)**  
**COP No.13774**



**PROFILE OF CA VIPUL V DHAMSANIA**

CA Vipul V Dhamsania is in practice since August 2011

He is founder partner of M/S V Dhamsania & Associates

He has obtained the certificate of Concurrent Audit of bank, issued by the ICAI

He has also obtained the certificate of Blockchain technology issued by the ICAI

Main area of practice of CA Vipul V Dhamsania is Audit, Income Tax law consultancy, GST law consultancy and Corporate law consultancy





### **ABOUT THE FIRM**

Registered with Institute of Chartered Accountants of India since 2011, V Dhamsania & Associates is a leading CA firm with young, enthusiastic and experienced partners providing expert professional services. With due care of professional ethics. We provide efficacious solution to our client's business need with respect to legal advisory services and other engagement services.

We believe in partnering with our clients. We tailor our services to meet client's specific need with respect to its business organization, which provide a one stop solution to all services related to business management and statutory compliance.

We have highly talented, trained, capable and qualified professional team which provide best solution to any business need. Serving to the wider business community under the direction of partners with team of around 25 people, we enjoy respect and reputation of our clients, who trust and rely on us.

### **PROFILE OF THE FIRM**

Name of the Firm	V Dhamsania & Associates
Constitution	Partnership Firm
Date of Establishment	25/08/2011



Bhavnagar: 320, Imperial Arc, Opp University Gate, Waghawadi Road, Bhavnagar-364001

Surat: Office No.-1, Tulsi Arcade, Opp. Gabani Hospital, Station Road, Surat-395003

Cell : +91 - 9898027172 / Phone No : 0278-2570300

E-Mail : vipuldhamsania@gmail.com



Address of Offices	1) <u>Head Office at Bhavnagar</u> 320, Imperial Arc, Opp University Gate, Waghwadi Road, Bhavanagar – 364001 Gujarat, India.  2) <u>Branch at Surat</u> Office No.-1, Tulsi Arcade, Opp Gabani Hospital, Station Road, Surat – 395003, Gujarat, India.
Certificate course on Concurrent Audit completed by partners	(1) Vipul V Dhamsania Year of Passing 2016
FCA Partners	(1) Vipul V Dhamsania Date of FCA : 26/12/2016
PAN	AAQFV0092F
GST Registration No.	24AAQFV0092F1Z3
Registration No. Of Firm with ICAI	132499W
Peer Review Certificate No. & Date	Certificate No.-011546 Dt.11/02/2019
Unique Code No for Bank Audit	1010099
Latest Grade suggested by RBI for Statutory Branch Audit as available on website <a href="http://www.meficai.org">www.meficai.org</a>	III
CAG Empanelment No.	WR4174
Manpower (Nos)	A) Qualified Professionals: (i) Partners : 2 (ii) Others : 4 B) Other Audit Staff : 10

